Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors

Neoplasia

Volumn 2, Issue 1-2, 2000, Pages 71-88

  Mankoff, David A ^a,d   Dehdashti, Farrokh ^b   Shields, Anthony F ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Division of Nuclear Medicine   (United States)

Author keywords

Cellular proliferation; Estrogen receptors; Oncology; PET; Response

Indexed keywords

CARBON 11; CLEVUDINE; DNA; ESTROGEN RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE; NUCLEOSIDE TRIPHOSPHATE; NUCLEOTIDE; PROGESTERONE RECEPTOR; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; STEROID RECEPTOR; THYMIDINE; THYMIDINE DERIVATIVE;

CELL PROLIFERATION; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR;

EID: 0034087594     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900075     Document Type: Review

References (153)

1. Tannock IF, and Hill RP (1992). The Basic Science of Oncology, McGraw-Hill, New York.
2. Sledge GJ, and McGuire W (1983). Steroid hormone receptors in human breast cancer. Adv Cancer Res 38, 61-75.
3. McGuire W, and Horwitz K (1975). Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189, 726-727.
4. Muss H, Thor A, Berry D, et al. (1994). C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330, 1260-1266.
5. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, and Gomez F (1986). The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: clinical correlation on 547 patients. Cancer 57, 1170-1180.
6. Livingston R, and Ellis G (1995). Breast cancer: dose response and intensity. Cancer Chemother 10, 17-26.
7. Hoehn J, Plotka E, and Dickson K (1979). Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg 190, 69-71.
8. Holdaway I, and Bowditch J (1983). Variation in receptor status between primary and metastatic breast cancer. Cancer 52, 479-485.
9. Kamby C, Rasmussen BB, and Kristensen B (1989). Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60, 252-257.
10. Husband JE (1996). Monitoring tumor response. Eur Radiol 6, 775-785.
11. Radford JA, Cowan RA, Flanagan M, et al. (1989). The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 6, 940-946.
12. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, and Blumenschein GR (1986). Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46, 2578-2581.
13. Livingston RB, and Hart JS (1977). The clinical applications of cell kinetics in cancer therapy. Annu Rev Toxicol 17, 529-543.
14. Chang J, Powles T, Allred D, et al. (1999). Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17, 3058-3063.
15. Katzenellenbogen JA, Coleman RE, Hawkins RA, et al. (1995). Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res 1, 921-932.
16. Strauss L, and Conti P (1991). The application of PET in clinical oncology. J Nucl Med 32, 623-647.
17. Jones T (1996). The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med 23, 207-211.
18. Shields AF, Graham MM, and Spence AM (1995). The role of PET imaging in clinical oncology. In Nuclear Medicine Annual 1995. LM Freeman (Ed). Raven Press, New York. pp. 129-168.
19. Rigo P, Paulus P, Kaschten BJ, et al. (1996). Oncological applications of positron emission tomography with fluoro-D-glucose. Eur J Nucl Med 23, 1641-1674.
20. Eary J (1999). Nuclear medicine in oncology diagnosis. Lancet 354, 853-857.
21. 11C]deoxyglucose. J Cereb Blood Flow Metab 5, 179-192.
22. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28, 897-916.
23. Smith TA (1998). FDG uptake, tumor characteristics and response to therapy: a review. Nucl Med Commun 19, 97-105.
24. Strauss L (1996). Fluorine-18 deoxyglucose and false-positive results:a major problem in the diagnostics of oncological patients. Eur Journal Nucl Med 23, 1409-1415.
25. Strauss LG (1997). Positron emission tomography: a current role for diagnosis and therapy monitoring in oncology. Oncologist 2, 381-388.
26. Shields AF, Ho PT, and Grierson JR (1999). The role of imaging in the development of oncologic agents. J Clin Pharmacol 39, Suppl, 40S-44S.
27. Price P, and Jones T (1995). Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET oncology concerted action and the EORC PET study group. Eur J Cancer 31, 1924-1927.
28. Huovinen R, Leskinen-Kallo S, Nagren K, et al. (1993). Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67, 787-791.
29. Kole A, Pruim J, Nieweg O, et al. (1997). PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates. J Nucl Med 38, 191-195.
30. 11C]choline. J Nucl Med 38, 842-847.
31. Rasey JS, Koh W, Grierson JR, Grunbaum Z, and Krohn KA (1989). Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 17, 985-992.
32. Andrich MP, and Neumann R (1994). The role of positron emission tomography imaging in early assessment of the antitumor impact on biologics and cytotoxics. Curr Opin Oncol 6, 627-632.
33. Price P, Harte R, Wells P, et al. (1997). The potential of tracer kinetic studies in drug development programs: a new investigational area for cancer research. Drug Inf J 31, 1045-1049.
34. Tannock IF (1992). Cell proliferation. In The Basic Science of Oncology. IF Tannock, and RP Hill (Eds). McGraw-Hill, New York. pp. 154-177.
35. Cleaver JE (1967). Thymidine metabolism and cell kinetics. Front Biol 6, 43-100.
36. Wohlhueter RM, Marz R, and Plagemann PG (1979). Thymidine transport in cultured mammalian cells. Kinetic analysis, temperature dependence and specificity of the transport system. Biochim Biophys Acta 553, 262-283.
37. Livingston RB, Ambus U, George SL, Freireich EJ, and Hart JS (1974). In vitro determination of thymidine-[H-3] labeling index in human solid tumors. Cancer Res 34, 1376-1380.
38. Christman D, Crawford EJ, Friedkin M, and Wolf AP (1972). Detection of DNA synthesis in intact organisms with positron-emitting methyl-[C-11]-thymidine. Proc Natl Acad Sci U S A 69, 988-992.
39. 11C labeled thymidine for tumor visualization using Positron Emission Tomography. Int J Appl Radiat Isot 35, 705-708.
40. 11C]thymidine for quantification of cellular proliferation with PET. Appl Radiat Isot 42, 103-104.
41. Link JM, Grierson J, and Krohn K (1995). Alternatives in the synthesis of 2-[C-11]-thymidine. J Labelled Compd Radiopharm 37, 610-612.
42. Conti PS, Hilton J, Wong DF, et al. (1994). High performance liquid chromatography of carbon-11 labeled thymidine and its mjor carabolites for clinical PET studies. Nucl Med Biol 21, 1045-1051.
43. Goethals P, Eijkeren Mv, Lodewyck W, and Dams R (1995). Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors. J Nucl Med 36, 880-882.
44. Goethals P, Lameire N, van Eijkeren M, et al. (1996). [Methyl-carbon-11]thymidine for in vivo measurement of cell proliferation. J Nucl Med 37, 1048-1052.
45. Shields AF, Mankoff DA, Graham MM, et al. (1996). Analysis of 2-[C-11]-thymidine blood metabolites in PET imaging. J Nucl Med 37, 290-296.
46. Shields AF, Graham MM, Kozawa SM, et al. (1992). Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 33, 581-584.
47. 2 into the acid-labile, the acid-soluble, the lipid, the protein and the nucleic acid fractions of rat brain tissue. Acta Physiol Scand 64, 182-192.
48. Lockwood AH, and Finn RD (1982). [C-11]-carbon dioxide fixation and equilibration in rat brain: effects on acid-base measurements. Neurology 32, 451-454.
49. Shields AF, Lim K, Grierson J, Link J, and Krohn KA (1990). Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 31, 337-342.
50. Mankoff DA, Shields AF, Graham MM, et al. (1998). Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39, 1043-1055.
51. 124I]-iodo-2′-deoxyuridine for functional PET imaging of cell proliferation. Nucl Med Biol 25, 359-365.
52. Bergstrom M, Lu L, Fasth KJ, et al. (1998). In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med 39, 1273-1279.
53. Tjuvajev J, Muraki A, Ginos J, et al. (1993). Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 34, 1152-1162.
54. Tjuvajev JG, Macapinlac HA, Daghighian F, et al. (1994). Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35, 1407-1417.
55. Kassis AI, Adelstein SJ, and Mariani G (1996). Radiolabeled nucleoside analogs in cancer diagnosis therapy. Q J Nucl Med 40, 301-319.
56. 18F-5-fluoro-2′-deoxyuridine in animals. Eur J Nucl Med 8, 258-261.
57. 18F-5-fluorouracil. VII. J Nucl Med 14, 63-64.
58. 18F-5-fluorouridine, a new probe for measuring the proliferation of tissue in vivo. Adv Enzyme Regul 20, 3-22.
59. Washtien WL, and Santi DV (1979). Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Cancer Res 39, 3397-3404.
60. Grierson JR, Shields AF, Zheng M, Kozawa SM, and Courter JH (1995). Radiosynthesis of labeled β-pseudothymidine ([C-11]-and [H-3]-methyl) and its biodistribution and metabolism in normal and tumored mice. Nuclear Med Biol 22, 671-678.
61. Shields AF, Grierson JR, Kozawa SM, and Zheng M (1996). Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 23, 17-22.
62. Phillips FS, Feinberg A, Chou T-C, et al. (1983). Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-idocytosine. Cancer Res 43, 3619-3627.
63. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 22, 783-789.
64. Conti P, Alauddin MM, Fissekis JD, and Wanatabe KA (1999). Synthesis of [F-18]-2-fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([F-18]FMAU) (abstract). J Nucl Med 40, 83P.
65. Flexner C, van der Horst C, Jacobson MA, et al. (1994). Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 170, 1394-1403.
66. Munch-Petersen B, Cloos L, Tyrsted G, and Eriksson S (1991). Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 266, 9032-9038.
67. Shields AF, Grierson JR, Dohmen BM, et al. (1998). Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4, 1334-1336.
68. Larson SM, Weiden PL, Grunbaum Z, et al. (1981). Positron imaging feasibility studies I: characteristics of [H-3]-thymidine uptake in rodent and canine neoplasms: concise communication. J Nucl Med 22, 869-874.
69. Shields AF, Larson SM, Grunbaum Z, and Graham MM (1984). Short-term uptake in normal and neoplastic tissues: studies for PET. J Nucl Med 25, 759-764.
70. Schmall B, Conti P, Schaeffer D, and Kleinert E (1992). Tumor and organ biochemical profiles in vivo following uptake of a combination of radiolabeled substrates: a potential application for PET. Am J Physiol Imaging 7, 2-11.
71. Tew KD, and Taylor DM (1978). The relationship of thymidine metabolism to the use of fractional incorporation as a measure of DNA synthesis in tissue proliferation. Eur J Cancer 14, 153-168.
72. Higashi K, Clavo AC, and Wahl RL (1993). In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 34, 773-779.
73. 3H]thymidine, and gallium-67. J Nucl Med 32, 2118-2123.
74. Kuebbing D, and Werner R (1975). A model for compartmentation of de novo and salvage thymidine nucleotide pools in mammalian cells. Proc Natl Acad Sci U S A 72, 3333-3336.
75. Shields AF, Coonrod DV, Quackenbush RC, and Crowley JJ (1987). Cellular sources of thymidine nucleotides: studies for PET. J Nucl Med 28, 1435-1440.
76. Martiat P, Ferrant A, Lambar D, et al. (1988). In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 29, 1633-1637.
77. 11C-thymidine activity in human head and neck tumors using positron emission tomography (PET). Oncol 31, 539-543.
78. Mankoff DA, Shields AF, Link JM, et al. (1999). Kinetic analysis of 2-[C-11]thymidine PET imaging studies: validation studies. J Nucl Med 40, 614-624.
79. Patlak C, Dhawan V, Takikawa S, et al. (1993). Estimation of striatal uptake rate constant of FDOPA using PET: methodologic issues. In Quantification of Brain Function. Tracer Kinetics and Image Analysis in Brain PET. K Uemera, et al. (Eds). Elsevier Science Publishers, Amsterdam, Netherlands.
80. Mankoff DA, Shields AF, Graham MM, Link JM, and Krohn KA (1996). A graphical analysis method to estimate blood-tissue transfer constants for systems with labeled metabolites. J Nucl Med 37.
81. Cunningham V, Ashburner J, Byrne H, and Jones T (1993). Use of spectral analysis to obtain images from dynamic PET studies. In Quantification of Brain Function: Tracer Kinetics and Image Analysis in PET. Uemera K, et al. (Eds). Elsevier, Amsterdam. pp. 101-108.
82. Young H, Brock C, Wells P, and Price P (1999). Monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography (PET). Drug Inf J 33, 237-244.
83. Cunningham V, and Jones T (1993). Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13, 15-23.
84. O'Sullivan F (1993). Imaging radiotracer model parameters in PET: a mixture analysis approach. IEEE Trans Med Imag 12, 399-412.
85. Eary JF, Mankoff DA, Spence AM, et al. (1999).2-[C-11]-thymidine imaging of malignant brain tumors. Cancer Res 59, 615-621.
86. Cornford EM, and Oldendorf WH (1975). Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim et Biophys Acta 394, 211-219.
87. Kriss JP, Maruyama Y, Tung LA, Bond SB, and Revesz L (1963). The fate of 5-bromodeoxycytodine and 5-iododeoxyruridine in man. Cancer Res 23, 260-273.
88. 1311-5-iodo-2-deoxyuridine by malignant tumours in man. Br J Cancer 63, 134-135.
89. 11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol 35, 737-741.
90. 11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg 99, 118-125.
91. Shields AF, Mankoff DA, Link JM, et al. (1998). Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39, 1757-1762.
92. Vander Borght T, Pauwels S, Lambotte L, et al. (1994). Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 35, 974-982.
93. Santen RJ, Manni A, Harvey H, and Redmond C (1990). Endocrine treatment of breast cancer in women. Endocr Rev 11, 221-265.
94. Blankenstein MA B-dVJ, van Aubel OG, van Steenbrugge GJ (1988). Hormone receptors in human prostate cancer. Scan J Urol Nephrol 107, 39-45.
95. Brennan M, Donegan W, and Appleby D (1979). The variability of estrogen receptors in metastatic breast cancer. Am J Surg 137, 260-262.
96. McCarty KS, Miller LS, Cox EB, Konrath J, and McCarty KS (1985). Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109, 716-721.
97. Hull D, Clark G, Osborne C, et al. (1983). Multiple estrogen receptor assays in human breast cancer. Cancer Res 43, 413-416.
98. Barrack ER, and Tindall DJ (1987). A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. In Current Concepts and Approaches to the Study of Prostatic Cancer. D Coffey (Ed). Alan R. Liss, New York. pp. 155-187.
99. Ekman P, Dahlberg E, Gustafsson J, et al. (1980). Present and future clinical value of steroid receptor assays in human prostatic carcinoma. In Hormones and Cancer. S Lacobelli (Ed). Raven Press, New York, NY. pp. 361-370.
100. Katzenellenbogen J (1981). The development of gamma-emitting hormone analogs as imaging agents for receptor-positive tumors. In The Prostatic Cell: Structure and Function Part B. G Murphy, and A Sandberg (Eds). Alan R. Liss, New York. pp. 313-327.
101. Sadi M, and Barrack E (1993). Image analysis of androgen receptor immunostaining in metastatic prostate cancer: heterogeneity as a predictor of response to hormonal therapy. Cancer 71, 2574-2580.
102. Smith DC (1999). Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am 26, 323-331.
103. Isaacs JT (1999). The biology of hormone refractory prostate cancer. How does it develop? Urol Clin North Am 26, 323-331.
104. Katzenellenbogen JA, Welch MJ, and Dehdashti F (1997). The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17, 1573-1576.
105. Katzenellenbogen J (1992). The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In Radiopharmaceuticals: Chemistry and Pharmacology. A Nunn (Ed). Marcel Dekker, New York. pp. 297-331.
106. 18F]fluoroestradiols: selective receptor-based PET imaging agents. Int J Rad Appl Instrum Part B 19, 363-374.
107. 18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sci 53, 811-819.
108. Katzenellenbogen J, Heiman D, Senderoff S, et al. (1982). Estrogen receptor-based agents for imaging breast tumors: binding selectivity as a basis for design and optimization. In Applications of Nuclear and Radiochemistry. N Morcos, and R Lambrecht (Eds). Pergamon Press, New York. pp. 311-323.
109. Buckman B, Bonasera T, Kirschbaum K, Welch M, and Katzenellenbogen J (1995). Fluorine-18-labeled progestin 16α, 17α-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem 38, 328-337.
110. Kilbourn M, and Zalutsky M (1985). Research and clinical potential of receptor based radiopharmaceuticals. J Nucl Med 26, 655-662.
111. Brandes S, and Katzenellenbogen J (1988). Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate. Radiat Appl Instrum 15, 53-67.
112. Hammond G (1993). Steroid hormone action. In Extracellular Steroid-Binding Proteins. M Parker (Ed). Oxford University Press, New York. pp. 210.
113. Tait J, and Tait S (1991). The effect of plasma protein binding on the metabolism of steroid hormones. J Endocrinol 131, 339-357.
114. Petra P (1991). The plasma sex steroid binding protein (SBP or SBHG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 40, 735-753.
115. Hyrb D, Khan M, Romas N, and Rosner W (1990). The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J Biol Chem 265, 948-954.
116. Hobbs C, Jones R, and Plymate S (1992). The effects of sex hormone-binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid. J Steroid Biochem Mol Biol 42, 629-635.
117. Eckelman W (1992). The development of single-photon emitting receptor-binding radiotracers. In Radiopharmaceuticals: Chemistry and Pharmacology. A Nunn(Ed). Marcel Dekker, New York. pp. 167-219.
118. Cummins C (1993). Radiolabeled steroidal estrogen in cancer research. Steroids 58, 245-259.
119. Katzenellenbogen J, Hsiung H, Carlson K, et al. (1975). Iodohexestrols II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives in vitro and in vivo. Biochemistry 14, 1742-1750.
120. 77Br]bromoestradiol: dosimetry and preliminary clinical studies. J Nucl Med 23, 425-430.
121. 18F]fluoronorhexestrol): a positron-emitting estrogen that shows highly selective, receptor-mediated uptake by target tissues in vivo. Life Sci 33, 1933-1938.
122. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. (1984). Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissue of immature rats. J Nucl Med 25, 1212-1221.
123. Kieswetter D, Katzenellenbogen J, Kilbourn M, and Welch M (1984). Synthesis of 16-fluoroestrogens by unusually facile fluoride ion displacement reactions: prospects for the preparation of fluorine-18 labeled estrogens. J Org Chem 49, 4900-4905.
124. Brodack J, Kilbourn M, and Welch M (1986). Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18 16α-fluoroestradiol-17β. J Nucl Med 27, 714-721.
125. Tewson TJ (1995). The routine synthesis of fluorine-18 16α-fluoroestradiol: the use of 3-methoxymethyl-epiestriol-16β,17β-cyclic sulfate as the starting substrate. J Labelled Compd Radiopharm 37, 589-591.
126. 18F]Fluoroesrtradiol for breast cancer imaging. Nucl Med Biol 26, 473-479.
127. Jonson SD, and Welch MJ (1998). PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42, 8-17.
128. 18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 26, 123-130.
129. 18F]flourotamoxifen for imaging breast tumors. J Drug Target 1, 259-267.
130. Yang DJ, Li C, Kuang LR, et al. (1994). Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 55, 53-67.
131. 18F]fluoro-16 α-ethyl-19-norprogesterone: syntheses and target tissue selective uptake of a progestin receptor for positron emission tomography. J Med Chem 31, 1360-1363.
132. Pomper M, Pinney K, Carlson K, and et al. (1990). Target tissue uptake selectivity of three fluorine-substituted progestins: potential imaging agents for receptor-positive breast tumors. Nucl Med Biol 17, 309-319.
133. Verhagen A, Elsinga PH, Groot TJd, et al. (1991). A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography. Cancer Res 51, 1930-1933.
134. Kontula K, Jänne O, Vihko R, et al. (1975). Progesterone-binding proteins: in vitro binding and biological activity of different steroidal ligands. Acta Endocrinol 78, 574-592.
135. 18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 21, 941-952.
136. 18F]fluoro-16 alpha-ethyl-19-nonprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 32, 1532-1537.
137. Liu A, Dence C, Welch M, and Katzenellenbogen J (1992). Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 33, 724-734.
138. Bonasera T, O'Neil J, Xu M, et al. (1996). Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 37, 1009-1015.
139. 18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Radiat Appl Instrum 14, 15-25.
140. Mintun MA, Welch MJ, Siegel BA, et al. (1988). Breast cancer: PET imaging of estrogen receptors. Radiology 169, 45-48.
141. Katzenellenbogen JA, Mathias CJ, Vanbrocklin HF, Brodack JW, and Welch MJ (1993). Titration of the in vivo uptake of 16alpha-[F-18]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl Med Biol 20, 735-745.
142. 18F]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 24, 341-348.
143. Moresco RM, Scheithauer BW, Lulcignani G, et al. (1997). Oestrogen receptors in meningiomas: a correlative pet and immunohistochemical study. Nucl Med Commun 18, 606-615.
144. Tewson T, Mankoff D, Peterson L, Woo I, and Petra P (1999). The interactions of 16α-[F-18]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol in press.
145. Reventos J, Sullivan P, Joseph D, and Gordon J (1993). Tissue-specific expression of the rat androgen-binding protein/sex hormone-binding globulin gene in transgenic mice. Mol Cell Endocrinol 96, 69-73.
146. Dehdashti F, Mortimer JE, Siegel BA, et al. (1995). Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36, 1766-1774.
147. Dehdashti F, Flanagan FL, Mortimer JE, et al. (1999). Positron emission tomographic assessment of "metabolic flare" to predict response of metabolic breast cancer to antiestrogen therapy. Eur J Nucl Med 26, 51-56.
148. 18F] fluoro-17 beta-estradiol uptake in the metastatic breast carcinoma. J Nucl Med 32, 1526-1531.
149. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2, 933-939.
150. Plotkin D, Lechner JJ, Jung WE, and et al. (1978). Tamoxifen flare in advanced breast cancer. JAMA 240, 2644-2646.
151. Legha S (1988). Tamoxifen in the treatment of breast cancer. Ann Intern Med 109, 219-228.
152. Vogel CL, Schoenfelder J, Shemano I, and et al. (1995). Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13, 1123-1128.
153. Welch M, Bonasera T, Sherman E, and et al. (1995). fluoro-D-glucose (FDG) and 16α[F-18]fluoroestradiol-17β (FES) uptake in estrogen-receptor (ER) -rich tissues following tamoxifen treatment: a preclinical study (abstract). J Nucl Med 36, 39P.